



October 19, 2023

News Release

Company name: TMS Co., Ltd.
Name of representative: Takuro Wakabayashi, Chief Executive Officer
(Securities code: 4891; Growth Market)

TMS Co., Ltd. entered into Joint Research Agreement with Hokkaido University and Kanazawa University

TMS Co., Ltd. (the “Company”) announces today that the Company has completed the process for entering into a Joint Research Agreement with Hokkaido University and Kanazawa University. The effective date of the Joint Research started as of October 1, 2023.

Under the terms of the agreement, the Company will conduct pharmacological studies of drug candidate compounds generated by Hokkaido University for specific indications in collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the compounds as novel drugs. The agreement is based on an option agreement concluded with Hokkaido University dated May 8, 2023.

The candidate compounds were found out in the process of searching for drug seeds generated by academic institutions as part of the Company's efforts for expanding its pipeline. The candidate compounds have shown strong efficacy in animal models of specific diseases, and the Company is evaluating them because of its potential to address unmet medical needs.

The option agreement between the Company and Hokkaido University, on which this agreement is based, was supported by Gemseki Inc. (<https://www.gemseki.com/>, a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.), an intermediary for out-licensing and in-licensing of drug candidates and technology.

The impact on the Company's business performance for the current fiscal year is expected to be minimal.

About TMS Co., Ltd.

TMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases to address medical unmet needs. The Company's pipeline consists of a family of small compounds called SMTPs (*Stachybotrys microspora* triprenyl phenols) derived from a fungus. The lead pipeline compound, TMS-007, is indicated for the treatment of acute ischemic stroke. It demonstrated efficacy and safety in the completed Phase 2 study and was acquired by Biogen in 2021. Another SMTP compound, TMS-008, is under development for acute kidney injury and other potential indications. In addition, the Company is exploring new pipeline products by focusing on early-stage seeds from academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market. For more information about TMS, please visit <https://www.tms-japan.co.jp/>.

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Investor and Media Contact:
ir@tms-japan.co.jp

End